ERBB2 and neoplasm: We show that zanidatamab mediates antitumor activity in vitro and in vivo via multiple MOAs in HER2-expressing tumors, including increased tumor cell binding, HER2 internalization, suppression of cell signaling and tumor growth, as well as ADCC, and ADCP.